BOOK REVIEW

**HIGHLIGHTS**

ISBN: 9781466582675 − CAT# K18948
Book is edited by Xiaodong Feng, and Hong-Guang Xie;
Published by CRC Press, Taylor & Francis Group in January 2016. 308 pp., hardcover; there are 4 Color & 18 B/W Illustrations

---

**ABSTRACT**

*Applying Pharmacogenomics in Therapeutics* is intended to serve as an up-to-date reference book with a broad spectrum of the relevant fundamentals, principles, omics-related biotechnologies, and clinical practice. The whole book includes 11 chapters, each of which was written by pharmacologists and scientists of diverse experience from academia and biotech industry in the US and China.

**KEY WORDS**

Book review; pharmacogenomics; personalized therapy; omics

Received 12 July 2016; Revised 14 July 2016; Accepted 14 July 2016; Published 18 July 2016

**Ting Tai, MS*; Jin-Zi Ji, PhD**
General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, CHINA

*Corresponding author: taiting2015@outlook.com, Tel.: +86-25-52887003; Fax: +86-25-52269924
BOOK REVIEW

Applying Pharmacogenomics in Therapeutics is intended to serve as an up-to-date reference book with a broad spectrum of the relevant fundamentals, principles, omics-related biotechnologies, and clinical practice. The whole book includes 11 chapters, each of which was written by pharmacologists and scientists of diverse experience from academia and biotech industry in the US and China. Each chapter begins with the key concepts, and ends with important questions for the reader's self-examination, in between with either case reports discussed in depth, or genetic variants/biomarkers evaluated critically. This book provides real-world examples of pharmacogenomic applications in the drug development process and in patient care, helping make another bridge between pharmacogenomics and therapeutics. However, the coverage of the book seems to be limited, and thus new topics and context need to be expanded and updated in its future editions.

The book is organized into three parts. Part I (Chapters 1−5) describes the principles and practice of pharmacogenomics and its biotechnologies as well as genetic biomarkers in the drug discovery and development, laboratory medicine, and general clinical service, respectively. Part II (Chapters 6−9) focuses on the use of pharmacogenomics in cancers, cardiovascular diseases, neurologic and psychiatric disorders, and pulmonary diseases. And Part III (Chapters 10−11) addresses the merging of pharmacogenomics and alternative medicine, and the integration of pharmacogenomics into pharmacoconomics, respectively. Although the chapters provide varying levels of detail, some excellent chapters on specific topics are comprehensively reviewed, discussed thoughtfully, or nicely balanced, with elaborative illustrations added. The whole book provides a valuable resource for readers unfamiliar with pharmacogenomics or those new to the applications of pharmacogenomics in therapeutics. Therefore, the book can be recommended highly to use as a useful reference textbook or reading material, not casual reading, for the college students of special interest and health professionals considering their careers in academia, industry, official drug regulatory body, and clinical service, in particular clinicians for patient care who are facing new big challenges in the era of Precision Medicine, avoiding much of the unrealistic promise that always accompanies this topic or area.

CONFLICT OF INTEREST
The authors declare no competing interests.

ACKNOWLEDGEMENT
None.

FINANCIAL DISCLOSURE
None.

REFERENCES

Applying Pharmacogenomics in Therapeutics

Edited by Xiaodong Feng • Hong-Guang Xie